These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 26022569)

  • 21. Foreword.
    Etienne CF
    Vaccine; 2015 May; 33 Suppl 1():A1. PubMed ID: 25919148
    [No Abstract]   [Full Text] [Related]  

  • 22. Estimating the full public health value of vaccination.
    Gessner BD; Kaslow D; Louis J; Neuzil K; O'Brien KL; Picot V; Pang T; Parashar UD; Saadatian-Elahi M; Nelson CB
    Vaccine; 2017 Nov; 35(46):6255-6263. PubMed ID: 28986035
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Introducing new vaccines in developing countries.
    Kochhar S; Rath B; Seeber LD; Rundblad G; Khamesipour A; Ali M;
    Expert Rev Vaccines; 2013 Dec; 12(12):1465-78. PubMed ID: 24195483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How effectively can health care settings beyond the traditional medical home provide vaccines to adolescents?
    Schaffer SJ; Fontanesi J; Rickert D; Grabenstein JD; Rothholz MC; Wang SA; Fishbein D;
    Pediatrics; 2008 Jan; 121 Suppl 1():S35-45. PubMed ID: 18174319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gavi's balancing act: Accelerating access to vaccines while ensuring robust national decision-making for sustainable programmes.
    Sosler S; Kallenberg J; Johnson HL
    Vaccine; 2015 May; 33 Suppl 1():A4-5. PubMed ID: 25919172
    [No Abstract]   [Full Text] [Related]  

  • 26. Emerging issues in vaccine economics: perspectives from the USA.
    Lieu TA; Thompson KM; Prosser LA; O'Brien MA; Yusuf HR; Shefer AM; Weinstein MC; Rickert DL
    Expert Rev Vaccines; 2002 Dec; 1(4):433-42. PubMed ID: 12901581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How much does it cost to get a dose of vaccine to the service delivery location? Empirical evidence from Vietnam's Expanded Program on Immunization.
    Mvundura M; Kien VD; Nga NT; Robertson J; Cuong NV; Tung HT; Hong DT; Levin C
    Vaccine; 2014 Feb; 32(7):834-8. PubMed ID: 24370713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bridging the gap: need for a data repository to support vaccine prioritization efforts.
    Madhavan G; Phelps C; Sangha K; Levin S; Rappuoli R
    Vaccine; 2015 Jun; 33 Suppl 2(0 2):B34-9. PubMed ID: 26022565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conceptual frameworks and key dimensions to support coverage decisions for vaccines.
    González-Lorenzo M; Piatti A; Coppola L; Gramegna M; Demicheli V; Melegaro A; Tirani M; Parmelli E; Auxilia F; Moja L;
    Vaccine; 2015 Feb; 33(9):1206-17. PubMed ID: 25533328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economics of animal vaccination.
    McLeod A; Rushton J
    Rev Sci Tech; 2007 Aug; 26(2):313-26. PubMed ID: 17892154
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strategic costs and preferences revelation in the allocation of resources for health care.
    Levaggi L; Levaggi R
    Int J Health Care Finance Econ; 2010 Sep; 10(3):239-56. PubMed ID: 20309636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccination planning in Italy: increasing vaccines while reducing coverage?
    Garattini L; Curto A; Freemantle N
    Expert Rev Pharmacoecon Outcomes Res; 2016 Oct; 16(5):547-548. PubMed ID: 27441592
    [No Abstract]   [Full Text] [Related]  

  • 33. Economic evaluation of vaccines: specificities and future challenges illustrated by recent European examples.
    Postma MJ; Westra TA; Quilici S; Largeron N
    Expert Rev Vaccines; 2013 May; 12(5):555-65. PubMed ID: 23659302
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic evaluation of vaccination: capturing the full benefits, with an application to human papillomavirus.
    Bärnighausen T; Bloom DE; Cafiero ET; O'Brien JC
    Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():70-6. PubMed ID: 22882176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The ProVac initiative and evolving decision support.
    Sanderson CF
    Vaccine; 2015 May; 33 Suppl 1():A8-10. PubMed ID: 25919181
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparison of NITAG policies and working processes in selected developed countries.
    Ricciardi GW; Toumi M; Weil-Olivier C; Ruitenberg EJ; Dankó D; Duru G; Picazo J; Zöllner Y; Poland G; Drummond M
    Vaccine; 2015 Jan; 33(1):3-11. PubMed ID: 25258100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Achievements and challenges of resource allocation for health in a decentralized system in Tanzania: perspectives of national and district level officers.
    Nyamhanga T; Fruemnce G; Mwangu M; Hurtig AK
    East Afr J Public Health; 2013 Jun; 10(2):416-27. PubMed ID: 25130022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Desirable attributes of vaccines for deployment in low-resource settings.
    Chen D; Zehrung D
    J Pharm Sci; 2013 Jan; 102(1):29-33. PubMed ID: 23136115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Financing the delivery of vaccines to children and adolescents: challenges to the current system.
    Lindley MC; Shen AK; Orenstein WA; Rodewald LE; Birkhead GS
    Pediatrics; 2009 Dec; 124 Suppl 5():S548-57. PubMed ID: 19948587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economics and financing of vaccines for diarrheal diseases.
    Bartsch SM; Lee BY
    Hum Vaccin Immunother; 2014; 10(6):1568-81. PubMed ID: 24755623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.